

11/265,654

=> s 59-92-7/rn

L1 1 59-92-7/RN

=> d 11

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2007 ACS on STN

RN 59-92-7 REGISTRY

ED Entered STN: 16 Nov 1984

CN L-Tyrosine, 3-hydroxy- (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Alanine, 3-(3,4-dihydroxyphenyl)-, L- (8CI)

OTHER NAMES:

CN (-)-3,4-Dihydroxyphenylalanine

CN (-)-Dopa

CN (2S)-2-Amino-3-(3,4-dihydroxyphenyl)propanoic acid

CN β -(3,4-Dihydroxyphenyl)- α -L-alanine

CN β -(3,4-Dihydroxyphenyl)-L-alanine

CN β -(3,4-Dihydroxyphenyl)alanine

CN 3,4-Dihydroxy-L-phenylalanine

CN 3,4-Dihydroxyphenyl-L-alanine

CN 3,4-Dihydroxyphenylalanine

CN 3-(3,4-Dihydroxyphenyl)-L-alanine

CN 3-Hydroxy-L-tyrosine

CN Bendopa

CN Cidandopa

CN DA

CN Deadopa

CN Dihydroxy-L-phenylalanine

CN DOPA

CN Dopaflex

CN Dopaidan

CN Dopal

CN Dopalina

CN Dopar

CN Doparkine

CN Doparl

CN Dopasol

CN Dopaston

CN Dopaston SE

CN Dopastone

CN Dopastral

CN Dopicar

CN Doprin

CN Eldopal

CN Eldopar

CN Eldopatec

CN Eurodopa

CN Helfo-dopa

CN Insulamina

CN L-(-)-Dopa

CN L- β -(3,4-Dihydroxyphenyl)- α -alanine

CN L-3-(3,4-Dihydroxyphenyl)alanine

CN L-4,5-Dihydroxyphenylalanine

CN L-DOPA

CN Laradopa

CN Larodopa

CN Ledopa

CN Levodopa

11/265,654

CN Levopa
CN Maipedopa
CN Parda

ADDITIONAL NAMES NOT AVAILABLE IN THIS FORMAT - Use FCN, FIDE, or ALL for
DISPLAY

FS STEREOSEARCH

DR 25525-15-9, 23734-74-9, 72572-99-7, 72573-00-3, 90638-38-3, 88250-23-1,
34241-25-3

MF C9 H11 N O4


CI COM

LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN*, BIOSIS,
BIOTECHNO, CA, CABA, CAOLD, CAPLUS, CASREACT, CBNB, CHEMCATS,
CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, CSNB, DDFU, DRUGU, EMBASE, GMELIN*,
HSDB*, IFICDB, IFIPAT, IFIUDB, IMSPATENTS, IPA, MEDLINE, MRCK*,
NAPRALERT, PATDPASPC, PHAR, PROMT, PROUSDDR, PS, RTECS*, SPECINFO,
SYNTHLINE, TOXCENTER, TULSA, USAN, USPAT2, USPATFULL, USPATOLD, VETU
(*File contains numerically searchable property data)

Other Sources: EINECS**, NDSL**, TSCA**, WHO

(**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

12277 REFERENCES IN FILE CA (1907 TO DATE)

377 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

12294 REFERENCES IN FILE CAPLUS (1907 TO DATE)

17 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> s 83366-66-9/rn

L2 1 83366-66-9/RN

=> fil caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

2.85

3.96

FILE 'CAPLUS' ENTERED AT 15:03:16 ON 16 NOV 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is

11/265,654

strictly prohibited.

FILE COVERS 1907 - 16 Nov 2007 VOL 147 ISS 22
FILE LAST UPDATED: 15 Nov 2007 (20071115/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> d his

(FILE 'HOME' ENTERED AT 14:54:17 ON 16 NOV 2007)

FILE 'REGISTRY' ENTERED AT 14:54:30 ON 16 NOV 2007

FILE 'REGISTRY' ENTERED AT 15:02:10 ON 16 NOV 2007

L1 1 S 59-92-7/RN
L2 1 S 83366-66-9/RN

FILE 'CAPLUS' ENTERED AT 15:03:16 ON 16 NOV 2007

=> s l1

L3 12294 L1

=> s l2

L4 603 L2

=> s (parkinson disease OR "Parkinson's disease")

24842 PARKINSON
433 PARKINSONS
24889 PARKINSON
(PARKINSON OR PARKINSONS)
1006909 DISEASE
273525 DISEASES
1128917 DISEASE
(DISEASE OR DISEASES)
7069 PARKINSON DISEASE
(PARKINSON(W) DISEASE)
433 "PARKINSONS"
1006909 "DISEASE"
273525 "DISEASES"
1128917 "DISEASE"
("DISEASE" OR "DISEASES")
387 "PARKINSON'S DISEASE"
("PARKINSONS" (W) "DISEASE")
L5 7069 (PARKINSON DISEASE OR "PARKINSON'S DISEASE")

=> s l3 and l4

L6 34 L3 AND L4

=> s l6 and l5

L7 2 L6 AND L5

=> d l7 1-2 ibib kwic

L7 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2007:75882 CAPLUS
DOCUMENT NUMBER: 147:23476

11/265,654

TITLE: Influence of initial use of serotonergic antidepressants on antiparkinsonian drug use in levodopa-using patients
AUTHOR(S): Arbouw, Maurits E. L.; Movig, Kris L. L.; Neef, Cees; Guchelaar, Henk-Jan; Egberts, Toine C. G.
CORPORATE SOURCE: Faculty of Science, Division of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, 3508 TB, Neth.
SOURCE: European Journal of Clinical Pharmacology (2007), 63(2), 181-187
CODEN: EJCPAS; ISSN: 0031-6970
PUBLISHER: Springer
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ST serotonergic antidepressant antiparkinsonian levodopa Parkinson disease depression
IT 50-47-5, Desipramine 50-48-6, Amitriptyline 50-49-7, Imipramine 59-92-7, Levodopa, biological studies 72-69-5, Nortriptyline 303-49-1, Clomipramine 1668-19-5, Doxepine 10262-69-8, Maprotiline 19794-93-5, Trazodon 34911-55-2, Bupropion 54739-18-3, Fluvoxamine 54910-89-3, Fluoxetine 59729-33-8, Citalopram 61869-08-7, Paroxetine 79617-96-2, Sertraline 83366-66-9, Nefazodone 85650-52-8, Mirtazepine 93413-69-5, Venlafaxine
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(initial use of serotonergic antidepressants is not associated with use of antiparkinsonian drug in levodopa-using patients)

L7 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:995776 CAPLUS
DOCUMENT NUMBER: 141:406120
TITLE: Compositions and methods for the treatment of parkinson's disease and tardive dyskinesias with quinoline ring-containing neuromelanin-binding compounds
INVENTOR(S): Nelson, Jodi
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 24 pp., Cont.-in-part of U.S. Ser. No. 192,414.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004229908	A1	20041118	US 2003-616692	20030709
US 6417177	B1	20020709	US 2000-615639	20000713
US 2002198231	A1	20021226	US 2002-192414	20020709
PRIORITY APPLN. INFO.:			US 1999-143767P	P 19990713
			US 2000-175051P	P 20000107
			US 2000-202140P	P 20000505
			US 2000-615639	A2 20000713
			US 2002-192414	A2 20020709
			US 2003-479748P	P 20030619

IT 132-22-9, Chlorpheniramine
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (treatment of parkinsons disease and tardive dyskinesias using neuromelanin-binding quinoline analogs and adjuvants such as cytochrome P 450 inhibitors and dopamine modulators)

IT 59-92-7, Levodopa, biological studies
 RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (treatment of parkinson's disease and tardive dyskinesias using neuromelanin-binding quinoline analogs and adjuvants such as cytochrome P 450 inhibitors and dopamine modulators)

IT 50-52-2, Thioridazine 50-53-3, Chlorpromazine, biological studies
 50-63-5, Chloroquine diphosphate 51-61-6, Dopamine, biological studies
 51-61-6D, Dopamine, precursors, biological studies 52-86-8, Haloperidol
 54-05-7, Chloroquine 56-54-2, Quinidine 58-38-8, Prochlorperazine
 58-39-9, Perphenazine 58-40-2, Promazine 60-99-1, Levomepromazine
 69-23-8, Fluphenazine 113-59-7, Chlorprothixene 114-07-8, Erythromycin
 117-89-5, Trifluoperazine 118-42-3, Hydroxychloroquine 134-31-6,
 8-Quinolinol sulfate 147-84-2, biological studies 303-49-1,
 Clomipramine 364-62-5, Metoclopramide 442-96-6 1915-92-0
 1951-25-3, Amiodarone 1977-10-2, Loxapine 2062-78-4, Pimozide
 2739-16-4, 3,4-Dihydro-1-(2H)-quinolinecarboxaldehyde 3313-26-6,
 Thiothixene 4169-19-1, 1-Acetyl-1,2,3,4-tetrahydroquinoline 5002-47-1,
 Fluphenazine decanoate 5588-33-0, Mesoridazine 6168-85-0 7416-34-4,
 Molindone 24283-71-4, 1-Butyryl-1,2,3,4-tetrahydroquinoline 32571-37-2
 42399-41-7, Diltiazem 51481-61-9, Cimetidine 53462-15-0 54739-18-3,
 Fluvoxamine 54910-89-3, Fluoxetine 61869-08-7, Paroxetine
 65277-42-1, Ketoconazole 66357-35-5, Ranitidine 71320-77-9,
 Moclobemide 74050-97-8, Haloperidol decanoate 79617-96-2, Sertraline
 81103-11-9, Clarithromycin 83366-66-9, Nefazodone 83891-03-6,
 Norfluoxetine 84371-65-3, Mifepristone 84625-61-6, Itraconazole
 85721-33-1, Ciprofloxacin 86166-07-6 86386-73-4, Fluconazole
 91161-71-6, Terbinafine 99218-67-4 116644-53-2, Mibefradil
 127779-20-8, Saquinavir 136817-59-9, Delavirdine 150378-17-9,
 Indinavir 155213-67-5, Ritonavir 159989-64-7, Nelfinavir
 169590-42-5, Celecoxib 319912-96-4 319912-97-5 319912-98-6
 319913-01-4 319913-02-5 319913-03-6 319913-04-7 319913-05-8
 319913-08-1 478784-57-5 478784-58-6 478784-60-0 478784-61-1
 478784-65-5 478784-66-6 478784-67-7 478784-68-8 478784-70-2
 478784-71-3 645406-28-6 645406-30-0 645406-32-2 645406-38-8
 645406-39-9 645406-40-2 645406-41-3 645406-46-8 645406-47-9
 645406-48-0 645406-49-1
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (treatment of parkinson's disease and tardive dyskinesias using neuromelanin-binding quinoline analogs and adjuvants such as cytochrome P 450 inhibitors and dopamine modulators)

=> FIL STNGUIDE

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

14.37

18.33

FILE 'STNGUIDE' ENTERED AT 15:07:31 ON 16 NOV 2007

USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

11/265,654

FILE CONTAINS CURRENT INFORMATION.

LAST RELOADED: Nov 9, 2007 (20071109/UP).

=>

Connection closed by remote host